Drug intelligence / Profile preview

nogapendekin alfa inbakicept + sacituzumab govitecan

Development stage: Unknown
Lead developer: ImmunityBio
Modality: Small Molecules, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravesical, Intravenous

Overview

This is a combination of two drugs: **nogapendekin alfa inbakicept** and **sacituzumab govitecan**. Nogapendekin alfa inbakicept is an interleukin-15 receptor agonist, designed to stimulate the immune system by activating and proliferating natural killer cells and CD8+ memory T cells, thereby enhancing anti-tumor immunity. It is approved for use with Bacillus Calmette–Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ[1][2][5]. Sacituzumab govitecan is an antibody-drug conjugate targeting Trop-2, delivering the cytotoxic payload SN-38 to tumor cells expressing this antigen; it is approved for metastatic triple-negative breast cancer and other indications. There are no known approvals or clinical trials specifically evaluating the combination of these two agents together as a single therapy.

Brand names: Anktiva (for nogapendekin alfa inbakicept)Trodelvy (for sacituzumab govitecan)
Other names: nogapendekin alfa inbakicept-pmln (for nogapendekin alfa inbakicept)IMMU-132 (for sacituzumab govitecan)

Targets

TOP1 (DNA Topoisomerase I)IL15RA (Interleukin-15 receptor subunit alpha)TACSTD2 (Tumor-associated calcium signal transducer 2)

Beyond the preview

Go deeper on nogapendekin alfa inbakicept + sacituzumab govitecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nogapendekin alfa inbakicept + sacituzumab govitecan.

Explore the full profile